- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We're Reading: California Withdraws Request to Provide Insurance to Illegal Immigrants
What we're reading, January 19, 2017: California has withdrawn a request to sell health coverage for illegal immigrants; Pfizer's CEO pushes back against Donald Trump's depiction of the pharmaceutical industry; some Republican governors urge caution on Obamacare repeal.
With Donald J. Trump’s administration poised to enter the White House, California has backed off a request to sell unsubsidized health insurance to illegal immigrants. According to AP, Covered California was notified that the request in to CMS would face a 1-month comment period and a 180-day window for the final decision, which would let the decision fall to Trump’s administration. Currently, immigrants who do not have legal status can buy health coverage through an insurance agent.
One pharmaceutical executive is pushing back against Trump’s depiction of the industry. At the World Economic Forum in Davos, Switzerland, Pfizer’s CEO said pharmaceutical companies are not, as Trump said, “getting away with murder,” according to FiercePharma. Ian Read said the reputation that the pharmaceutical industry has gotten does not represent the ethical part of the industry. He distanced himself from Martin Shkreli, the former CEO of Turing Pharma, as well as Valeant Pharmaceuticals.
Some Republican governors are urging that Republican lawmakers show caution as they work to repeal the Affordable Care Act. Governors who have expanded Medicaid are concerned about the effect of repealing the healthcare law, reported The Wall Street Journal. Ohio Governor John Kasich will join at least 8 other governors and 2 lieutenant governors for a roundtable, Senate Finance Committee Republicans, on the future of Medicaid expansion.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
